SYNC-T

TM

Solid Tumor

Therapy Platform

Synchronizing In Situ Neoantigen T Cell Activation And Immuno-stimulation Via a Partial Oncolysis and Multi-Target Biologic Drug Combination Therapy

Cancer by the Numbers

Estimated number of people in the U.S. living with metastatic lung, breast, and prostate cancer

Syncromune is currently focused on developing therapies for metastatic non-small cell lung cancer, metastatic breast cancer, and metastatic castrate-resistant prostate cancer.  There is a large unmet need, as currently most metastatic solid tumor cancers are incurable.

Metastatic NSC Lung Cancer
0
Metastatic Breast Cancer
0
Metastatic Prostate Cancer
0

Source:  DelveInsight. Market Insight, Epidemiology, and Market Forecast – 2032.. mCRPC & mBC prevalence, US mNSCLC annual deaths, OUS mNSCLC incidence. Published September 2023.

The Challenge

Cancer has many mechanisms and ways to avoid, overwhelm, and suppress the immune system.  If only one or two of those mechanisms are targeted by a drug or therapy, cancer can compensate and use other means to overcome the immune system.  Currently, responses to immunotherapy vary by cancer type, and on average, only 15% to 30% of patients with solid tumors respond to single-target IV immunotherapy1, largely because of the multi-faceted immunosuppressive abilities of cancer. 

Ideally, combining two or more drugs could result in improved patient outcomes, but the combination of systemic IV immunotherapies thus far in metastatic castrate-resistant prostate cancer (mCRPC) trials and other treatment-resistant cancers have demonstrated limited benefit with high toxicities, adverse events, and discontinuation rates due to lack of tolerability 2,3.

Given the complex and multifactorial nature of the mechanisms mediating tumor immune evasion in mCRPC and other metastatic solid tumor cancers, it is becoming increasingly clear that cancer immunotherapy needs to implement a combination of numerous therapeutic agents that elicit multiple immuno-pharmacologic effects while also minimizing systemic autoimmune side effects.

SYNC-T:  A Novel Combination Multi-Target Approach

The SYNC-T Therapy Platform is Designed to:

Play Video

SYNC-T Animation: How it Works

Pipeline

Our current pipeline focuses on developing the SYNC-T platform therapy for metastatic solid tumor cancers.  You can learn more about SYNC-T trials HERE.

Key Scientific Presentations & Publications

Syncromune is committed to advancing science and developing cancer therapies to leverage the full potential of combination multi-target approaches. We strive to publish our trials as well as investigator-initiated work in peer-reviewed journals and present our data at medical congresses to contribute to furthering cancer research.  

American Association for Cancer Research (AACR) 2024 Annual Meeting     |     April 7, 2024     |     Presentation

Link, C.J. (2024, April 5-10). Systemic responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral infusion of multi-target immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). In Ecaterina Dubrava & Ulka N. Vaishampayan (Chairs), Cancer Vaccines: Ready for Prime Time?  [Conference presentation]. AACR 2024, San Diego, CA, United States.

American Association for Cancer Research (AACR) 2024 Annual Meeting     |     April 5-10, 2024     |     Poster Abstract

James B. DuHadaway, Alexander J. Muller, Lisa D. Laury-Kleintop, U. Margaretha Wallon, Susan K. Gilmour, Marie Webster, Jason R. Williams, Gabriela R. Rossi, Mario R. Mautino, Jonathan Lewis, Charles J. Link, George C. Prendergast. Cryo-immune vaccination (CIV) by SYNC-T therapy: Preclinical modeling of a novel device-multidrug immunotherapeutic approach to eradicate advanced metastatic cancers [poster abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB355.

REFERENCES

  1. Das SJohnson DB Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. 
  2. Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020 Oct 12;38(4):489-499.e3. doi: 10.1016/j.ccell.2020.08.007. Epub 2020 Sep 10. PMID: 32916128.
  3. Shenderov E, Boudadi K, Fu W, et al. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. Prostate. 2021 May;81(6):326-338. doi: 10.1002/pros.24110. Epub 2021 Feb 26. PMID: 33636027; PMCID: PMC8018565.

On this page you may select links to key publications from peer-reviewed journals as well as to materials presented at scientific conferences relating to Syncromune’s research and development of its product candidates. Investigational products and their uses mentioned on this website have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.  The content of each work is the property of the respective copyright holder and may not be further distributed without their express permission. The information in these materials may not be current or comprehensive, and Syncromune undertakes no obligation to correct or update such information.

SV-101

Metastatic Breast Cancer

Breast cancer deaths continue to rise each year in the U.S. and is the 2nd leading cause of cancer-related deaths among women worldwide.  Approximately 70% of all breast metastases spread to the bone, which is currently uncurable.

DISEASE FACTS & FIGURES

274,900

estimated patients in the U.S.

354,940

estimated patients in the OUS 6 major markets

SV-101

Metastatic Non-Small Cell Lung Cancer

A majority of patients have advanced disease at the time of diagnosis.  Lung cancer is the leading cause of cancer death for both men and women.  There is currently no cure for Stage III and IV lung cancer.

DISEASE FACTS & FIGURES

127,070

estimated patients in the U.S.

193,270

estimated patients in the OUS 6 major markets

SV-102

Metastatic Castrate-Resistant Prostate Cancer

Metastatic prostate cancer is on the rise each year in the U.S.  Changes in screening protocols has resulted in more men having advanced cancer at initial diagnosis.  There is currently a significant unmet need for effective treatment.

DISEASE FACTS & FIGURES

47,886

estimated patients in the U.S.

94,757

estimated patients in the OUS 6 major markets

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308